EUSA Pharma, a global biopharmaceutical company with a focus on oncology and rare disease, announced yesterday that it has named Jeffrey S Hackman as the new president of its US' operations.

Hackman will lead a major expansion of the company's US organisation, as the company completes its transatlantic commercial infrastructure. As part of its growth plans in the US, the company is establishing a new headquarters in Boston, Massachusetts, and rapidly increasing its sales, marketing, market access and medical teams. In the coming weeks, the company aims to launch a new sales force targeting key oncology and rare disease centres across the country, supported by a full medical and commercial team.

Hackman has 30 years' commercial pharmaceutical experience, including extensive expertise gained in the oncology field. He has a strong track record of building and leading commercial organisations and delivering business growth. He joins the company from rare disease company Novelion Therapeutics, where he was acting CEO. Prior to this he was senior VP and head of US Internal Medicine/Oncology at Shire Inc, following a period leading the company's US oncology franchise. Previously, he was responsible for establishing the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He also held senior roles in a number of other pharmaceutical companies.